Drug Interaction Study Between AZD3480 and Aripiprazole in Healthy Subjects

A Single-Centre, Double-Blind, Randomised, Parallel Group Study of Repeated Oral Doses of AZD3480/Placebo and a Single Dose of Aripiprazole to Evaluate the Pharmacokinetic Interaction Between AZD3480 and Aripiprazole in Healthy Subjects (Phase I)

The purpose of the study is to evaluate if AZD3480 and warfarin interact with each other or not, i.e. show the same or altered plasma concentration profiles when co-administered compared to administered alone.

Inclusion Criteria:

• Provision of signed written informed consent
• Clinically normal physical findings and laboratory values

Exclusion Criteria:

• Clinically significant illness or clinically relevant trauma within three weeks before the first dose
• History of clinically significant disease
• Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product